We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Time to Focus on Ligand Pharmaceuticals (LGND) for Strong Earnings Growth Potential
Read MoreHide Full Article
Growth stocks can be some of the most exciting picks in the market, as these high-flyers can captivate investors’ attention, and produce big gains as well. However, they can also lead on the downside when the growth story is over, so it is important to find companies which are still seeing strong growth prospects in their businesses.
One such company that might be well-positioned for future earnings growth is Ligand Pharmaceuticals Incorporated (LGND - Free Report) . This firm, which is in the Medical - Biomedical and Genetics industry, saw EPS growth of 51.6% last year, and is looking great for this year too.
In fact, the current growth estimate for this year calls for earnings-per-share growth of 94%. Furthermore, the long-term growth rate is currently an impressive 20%, suggesting pretty good prospects for the long haul.
Ligand Pharmaceuticals Incorporated Price and Consensus
And if this wasn’t enough, the stock has actually seen estimates rise over the past month for the current fiscal year by about 12.2%. Thanks to this rise in earnings estimates, LGND has a Zacks Rank #1 (Strong Buy) which further underscores the potential for outperformance in this company. You can see the complete list of today’s Zacks #1 Rank stocks here.
So, if you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider LGND. Not only does it have double-digit earnings growth prospects, but its impressive Zacks Rank suggests that analysts believe better days are ahead for LGND as well.
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits. Click here to see the 5 stocks >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Time to Focus on Ligand Pharmaceuticals (LGND) for Strong Earnings Growth Potential
Growth stocks can be some of the most exciting picks in the market, as these high-flyers can captivate investors’ attention, and produce big gains as well. However, they can also lead on the downside when the growth story is over, so it is important to find companies which are still seeing strong growth prospects in their businesses.
One such company that might be well-positioned for future earnings growth is Ligand Pharmaceuticals Incorporated (LGND - Free Report) . This firm, which is in the Medical - Biomedical and Genetics industry, saw EPS growth of 51.6% last year, and is looking great for this year too.
In fact, the current growth estimate for this year calls for earnings-per-share growth of 94%. Furthermore, the long-term growth rate is currently an impressive 20%, suggesting pretty good prospects for the long haul.
Ligand Pharmaceuticals Incorporated Price and Consensus
Ligand Pharmaceuticals Incorporated Price and Consensus | Ligand Pharmaceuticals Incorporated Quote
And if this wasn’t enough, the stock has actually seen estimates rise over the past month for the current fiscal year by about 12.2%. Thanks to this rise in earnings estimates, LGND has a Zacks Rank #1 (Strong Buy) which further underscores the potential for outperformance in this company. You can see the complete list of today’s Zacks #1 Rank stocks here.
So, if you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider LGND. Not only does it have double-digit earnings growth prospects, but its impressive Zacks Rank suggests that analysts believe better days are ahead for LGND as well.
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Click here to see the 5 stocks >>